Table 4

Associations between osteoprotegerin concentrations (continuous) and events during follow-up

	30 day outcomes				1 year outcomes
	Unadjusted		Adjusted		Unadjusted		Adjusted
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
CV death	4.67 (2.85 to 7.67)	<0.001	2.32 (1.30 to 4.17)	0.005	3.85 (2.92 to 5.08)	<0.001	1.85 (1.33 to 2.59)	<0.001
Severe recurrent ischemia	1.23 (0.90 to 1.69)	0.19	0.93 (0.65 to 1.33)	0.69	1.16 (0.95 to 1.40)	0.14	1.04 (0.83 to 1.29)	0.73
MI	1.57 (1.13 to 2.17)	0.006	1.11 (0.76 to 1.61)	0.59	1.67 (1.33 to 2.09)	<0.001	1.13 (0.87 to 1.46)	0.37
Hospitalisation for New or Worsening HF	4.70 (3.10 to 7.12)	<0.001	2.25 (1.38 to 3.69)	0.001	4.11 (3.04 to 5.54)	<0.001	1.81 (1.26 to 2.58)	0.001
CV death or MI	2.04 (1.53 to 2.71)	<0.001	1.35 (0.97 to 1.88)	0.072	2.17 (1.80 to 2.62)	<0.001	1.37 (1.10 to 1.70)	0.005
CV death or hospitalisation for new or worsening HF	4.38 (3.07 to 6.25)	<0.001	2.14 (1.40 to 3.25)	<0.001	3.55 (2.83 to 4.47)	<0.001	1.69 (1.28 to 2.22)	<0.001

HR associated with 1 SD increase in logarithmically transformed osteoprotegerin levels at baseline.
Adjusted for Thrombolysis in Myocardial Infarction risk score covariates (including cardiac marker), history of congestive heart failure, creatinine clearance <60 ml/min, gender, body mass index (continuous), B type natriuretic peptide (log transformed) and C reactive protein (log transformed).
CV, cardiovascular; HF, heart failure; MI, myocardial infarction.